Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
24.45
+0.23 (0.95%)
Apr 2, 2026, 11:40 AM EDT - Market open
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Beam Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $52.21, which forecasts a 113.54% increase in the stock price over the next year. The lowest target is $21 and the highest is $80.
Price Target: $52.21 (+113.54%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Beam Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 4 | 5 | 5 | 6 | 7 | 5 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 14 | 16 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $64 → $68 | Strong Buy | Maintains | $64 → $68 | +178.12% | Mar 26, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $22 → $26 | Hold | Maintains | $22 → $26 | +6.34% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Maintains $57 → $65 | Buy | Maintains | $57 → $65 | +165.85% | Feb 25, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $74 | Strong Buy | Initiates | $74 | +202.66% | Feb 20, 2026 |
| Bernstein | Bernstein | Buy Maintains $37 → $41 | Buy | Maintains | $37 → $41 | +67.69% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
50.61M
from 139.74M
Decreased by -63.78%
Revenue Next Year
70.68M
from 50.61M
Increased by 39.64%
EPS This Year
-4.67
from -0.81
EPS Next Year
-4.72
from -4.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 115.5M | 191.5M | |||
| Avg | 50.6M | 70.7M | |||
| Low | 34.3M | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -17.3% | 278.3% | |||
| Avg | -63.8% | 39.6% | |||
| Low | -75.5% | -34.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.71 | -3.40 | |||
| Avg | -4.67 | -4.72 | |||
| Low | -5.31 | -6.06 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.